A1H Stock Overview
Amoéba S.A. develops biological biocides for the prevention of microbiological risk for water treatment, human wounds, and plant protection.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Amoéba S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.35 |
| 52 Week High | €0.64 |
| 52 Week Low | €0.33 |
| Beta | -0.021 |
| 1 Month Change | -8.34% |
| 3 Month Change | 0.29% |
| 1 Year Change | -43.94% |
| 3 Year Change | -84.20% |
| 5 Year Change | -85.01% |
| Change since IPO | -97.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| A1H | DE Chemicals | DE Market | |
|---|---|---|---|
| 7D | 1.3% | -1.5% | -1.5% |
| 1Y | -43.9% | -1.1% | 0.9% |
Return vs Industry: A1H underperformed the German Chemicals industry which returned -1.3% over the past year.
Return vs Market: A1H underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| A1H volatility | |
|---|---|
| A1H Average Weekly Movement | 12.8% |
| Chemicals Industry Average Movement | 4.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: A1H's share price has been volatile over the past 3 months.
Volatility Over Time: A1H's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 22 | n/a | amoeba-nature.com |
Amoéba S.A. develops biological biocides for the prevention of microbiological risk for water treatment, human wounds, and plant protection. It develops applications by exploiting the characteristics of the amoeba Willaertia magna C2c Maky. The company was incorporated in 2010 and is based in Chassieu, France.
Amoéba S.A. Fundamentals Summary
| A1H fundamental statistics | |
|---|---|
| Market cap | €20.35m |
| Earnings (TTM) | -€14.30m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.4x
P/E RatioIs A1H overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A1H income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €1.71m |
| Gross Profit | -€1.71m |
| Other Expenses | €12.59m |
| Earnings | -€14.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 10.1% |
How did A1H perform over the long term?
See historical performance and comparison